Publications

European journal of cancer (Oxford, England : 1990)

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

01-05-2023

Journal of translational medicine

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.

18-04-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Cancer research communications

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

01-04-2023

Immuno-oncology technology

Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.

01-03-2023

British journal of cancer

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

01-03-2023

Cardiovascular and interventional radiology

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.

01-03-2023

Cancers

Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).

28-02-2023

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Melanoma research

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

01-02-2023

Cancers

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

07-01-2023

Annals of surgical oncology

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

01-01-2023

BMC cancer

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

30-12-2022

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

08-12-2022

Melanoma research

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

01-12-2022

Data in brief

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.

01-12-2022

JAMA oncology

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

01-12-2022

Cancers

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

19-11-2022

European journal of cancer (Oxford, England : 1990)

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

01-11-2022

Nature medicine

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

01-11-2022

European journal of cancer (Oxford, England : 1990)

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

01-11-2022

NEJM evidence

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

01-11-2022

JCO oncology practice

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.

01-10-2022

Journal of translational medicine

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

04-09-2022

JCO precision oncology

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.

01-09-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

01-09-2022

Immuno-oncology technology

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

01-09-2022

Clinica chimica acta; international journal of clinical chemistry

Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

01-08-2022

Annals of surgical oncology

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-08-2022

BJU international

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.

01-07-2022

Journal for immunotherapy of cancer

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

01-07-2022

Journal for immunotherapy of cancer

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.

01-07-2022

Annals of surgical oncology

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-06-2022

Nature medicine

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

01-06-2022

Journal of translational medicine

The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

10-05-2022

European journal of cancer (Oxford, England : 1990)

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.

01-05-2022

British journal of cancer

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-05-2022

Science translational medicine

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.

27-04-2022

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-04-2022

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

01-04-2022

JAMA surgery

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

01-04-2022

International journal of cancer

The unfavorable effects of COVID-19 on Dutch advanced melanoma care.

01-03-2022

Trials

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.

13-02-2022

European journal of cancer (Oxford, England : 1990)

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

01-02-2022

Journal of the European Academy of Dermatology and Venereology : JEADV

Survival of stage IV melanoma in Belgium and the Netherlands.

01-02-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

01-02-2022